NEW YORK, August 25, 2016 /PRNewswire/ --
Operators in the Medical Laboratories and Research segment provide healthcare practitioners with information concerning the onset, severity, and cause of patients' ailments and illnesses. Equities under evaluation on Stock-Callers.com are: VWR Corp. (NASDAQ: VWR), DexCom Inc. (NASDAQ: DXCM), Laboratory Corp. of America Holdings (NYSE: LH), and PerkinElmer Inc. (NYSE: PKI). Learn more about these stocks by downloading their free report at:
On Wednesday, Radnor, Pennsylvania-based VWR Corp.'s stock recorded a trading volume of 743,888 shares and ended the session 2.36% lower at $27.77. Shares of the Company, which together with its subsidiaries, operates as an independent provider of laboratory products, services, and solutions to the life science, general research, and applied markets, are trading 2.48% above its 200-day moving average. The stock has a Relative Strength Index (RSI) of 28.18.
On August 04th, 2016, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $33 a share to $34 a share.
As per notes filed with the SEC dated August 11th, 2016, on August 9th, 2016, VWR entered into an underwriting agreement with Merrill Lynch, Pierce, Fenner & Smith Incorporated, as underwriter, and the selling stockholder Varietal Distribution Holdings, LLC. The Underwriting Agreement relates to the sale by the Selling Stockholder to the underwriter of 8,000,000 shares of the Company's common stock, par value $0.01 per share. The underwriter may offer the Shares from time to time for sale in negotiated transactions or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices. The free research report on VWR is available at:
San Diego, California headquartered DexCom Inc.'s stock closed the day 1.89% lower at $90.35 and with a total volume of 797,856 shares traded. The Company's shares have advanced 2.30% in the past month, 39.06% in the previous three months, and 10.32% on an YTD basis. The stock is trading 8.05% above its 50-day moving average and 21.81% above its 200-day moving average. Additionally, shares of DexCom, which focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 57.96.
On August 03rd, 2016, research firm The Benchmark Company reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $86 a share to $106 a share.
On August 8th, 2016, DexCom announced the availability of enhanced data sharing features for physician and patient users of the DexCom CLARITY® diabetes management solution. DexCom CLARITY works with the DexCom G5® Mobile Continuous Glucose Monitoring System by automatically sending a patient's CGM data to a secure cloud-based system that can easily be accessed by the patient's health care professional. The complimentary report on DXCM can be downloaded at:
Laboratory Corp. of America Holdings
Shares in Burlington, North Carolina headquartered Laboratory Corp. of America Holdings recorded a trading volume of 593,766 shares. The stock ended yesterday's trading session 1.27% lower at $136.32. The Company's shares have advanced 6.85% in the previous three months. Furthermore, shares of Laboratory Corp. of America Holdings, which operates as an independent clinical laboratory company worldwide, have an RSI of 45.63.
On August 23rd, 2016, the company announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, applicable to the acquisition of Sequenom, Inc. has expired. As previously announced, Laboratory Corp. and Savoy Acquisition Corp., its direct wholly owned subsidiary, commenced a tender offer on August 9th, 2016, for all of the outstanding shares of common stock of Sequenom, including the associated preferred stock purchase rights, for $2.40 net to the seller in cash, without interest thereon and subject to applicable withholding taxes. Visit us today and download our complete research report on LH for free at:
Waltham, Massachusetts headquartered PerkinElmer Inc.'s stock finished the session 3.31% lower at $54.09 with a total volume of 590,014 shares traded. The Company's shares have advanced 1.39% since the start of this year. The stock is trading above its 200-day moving average by 5.34%. Additionally, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide, have an RSI of 46.65.
On August 4th, 2016, PerkinElmer reported GAAP earnings per share from continuing operations of $0.56 for Q2 2016 compared to $0.43 in Q2 2015. The company's GAAP revenue in Q2 2016 was $572.7 million compared to $563.9 million in the comparable period of 2015.
On August 05th, 2016, research firm Mizuho downgraded the Company's stock rating from 'Buy' to 'Neutral', issuing a target price of $56 per share. Get free access to your technical report on PKI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA